Evaluating the impact of leniolisib treatment on symptoms and health-related quality of life in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome.
- DOI
- 10.3389/fimmu.2026.1739437
- Published
- 2026
- Container
- Frontiers in immunology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2026.1739437,
title = {Evaluating the impact of leniolisib treatment on symptoms and health-related quality of life in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome.},
author = {Rao VK and Morgan A and Torgerson TR and Harrington A and Whalen J and Munro E and Luscombe J and de la Motte A and Romero B and Bahar R and Bradt J},
year = {2026},
journal = {Frontiers in immunology},
doi = {10.3389/fimmu.2026.1739437},
url = {https://doi.org/10.3389/fimmu.2026.1739437}
}RIS
TY - JOUR TI - Evaluating the impact of leniolisib treatment on symptoms and health-related quality of life in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome. AU - Rao VK AU - Morgan A AU - Torgerson TR AU - Harrington A AU - Whalen J AU - Munro E AU - Luscombe J AU - de la Motte A AU - Romero B AU - Bahar R AU - Bradt J PY - 2026 JO - Frontiers in immunology DO - 10.3389/fimmu.2026.1739437 UR - https://doi.org/10.3389/fimmu.2026.1739437 ER -
APA
VK, R., A, M., TR, T., A, H., J, W., E, M., J, L., A, D. L. M., B, R., R, B., & J, B. (2026). Evaluating the impact of leniolisib treatment on symptoms and health-related quality of life in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1739437
Source records
- pubmed · retrieved 2026-09-25T19:57:37.631Z